Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NINTOC-TU: Nintedanib and Tocilizumab in Systemic Sclerosis and Interstitial Lung Disease
NCT06297096Phase 3Recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib, tocilizumab in systemic sclerosis (SSc), interstitial lung disease (ILD). Started Jul 2025; status: recruiting.
02
Drugs
nintedanibtocilizumab
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06297096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297096.